In The Know: Analyst answers — What changes are coming for ovarian cancer treatment?

What does the future hold for ovarian cancer therapies? We sat down with senior KOL Insights analyst Sarah Harris to discuss her research into recent developments and what new therapies have potential to shake up the market over the next three-to-five years. Here she shares some key findings from in-depth interviews with key opinion leaders (KOLs) on the topic.

FirstWord: What was the main objective for this research?

Sarah Harris: The main objective was to look at recent events in ovarian cancer and to ascertain how leading KOLs in the field interpret them and what they anticipate the implications of these will be for the evolving treatment paradigm.


FW: Based on the research, what is the general sentiment from KOLs on the progression of the ovarian cancer treatment landscape?

SH: The use of PARP inhibitors continues to expand. The KOLs recognise that AstraZeneca’s dominance is set to continue, especially in light of the SOLO-1 trial of Lynparza meeting its endpoint of progression-free survival (PFS). Nonetheless, the experts also discuss how the competitive landscape is heating up with the recent extension to the EU approval of Rubraca. The recent FDA approval of first-line Avastin, plus chemotherapy, is also viewed as a welcome development for oncologists and patients alike.


FW: What is one of the most notable changes over the last few months in ovarian cancer treatment your research has found?

SH: The success of the SOLO-1 trial of Lynparza in meeting its PFS endpoint is of key importance as it could potentially pave the way for PARP inhibitors to transition to the first-line maintenance setting.


FW: What was one of the most insightful KOL interview quotes? What did it teach us?

SH: A European KOL explains how the SOLO-1 data could lead the way for PARP inhibitors to be used as front-line maintenance therapy, changing their positioning in the treatment algorithm: “This is potentially very exciting news. It could radically change the way in which we administer PARP inhibitors. At the moment, we're using PARP inhibitors entirely in recurrent disease settings [as] maintenance. With the SOLO-1 data, it's possible that for the BRCA-mutated subpopulation, we might use PARP inhibitors in the first-line setting and not in recurrent disease.”

To learn more about this recent research, click here.



To read more Sponsored Story articles, click here.